Global Influenza Vaccine Market Insights and Forecast to 2028

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Influenza Vaccine Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Influenza Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
  • 1.2.2 Trivalent Influenza Vaccine
  • 1.2.3 Quadrivalent Influenza Vaccine
• 1.3 Market by Application
  • 1.3.1 Global Influenza Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
  • 1.3.2 For Children (6 months to 3 years)
  • 1.3.3 For Adults and Children over 3 years
• 1.4 Study Objectives
• 1.5 Years Considered

2 Executive Summary

• 2.1 Global Influenza Vaccine Sales Estimates and Forecasts 2017-2028
• 2.2 Global Influenza Vaccine Revenue Estimates and Forecasts 2017-2028
• 2.3 Global Influenza Vaccine Revenue by Region: 2017 VS 2021 VS 2028
• 2.4 Global Influenza Vaccine Sales by Region
  • 2.4.1 Global Influenza Vaccine Sales by Region (2017-2022)
  • 2.4.2 Global Sales Influenza Vaccine by Region (2023-2028)
• 2.5 Global Influenza Vaccine Revenue by Region
  • 2.5.1 Global Influenza Vaccine Revenue by Region (2017-2022)
  • 2.5.2 Global Influenza Vaccine Revenue by Region (2023-2028)
• 2.6 North America
• 2.7 Europe
• 2.8 Asia-Pacific
• 2.9 Latin America
• 2.10 Middle East & Africa

3 Competition by Manufacturers

• 3.1 Global Influenza Vaccine Sales by Manufacturers
  • 3.1.1 Global Top Influenza Vaccine Manufacturers by Sales (2017-2022)
  • 3.1.2 Global Influenza Vaccine Sales Market Share by Manufacturers (2017-2022)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Influenza Vaccine in 2021
• 3.2 Global Influenza Vaccine Revenue by Manufacturers
  • 3.2.1 Global Influenza Vaccine Revenue by Manufacturers (2017-2022)
  • 3.2.2 Global Influenza Vaccine Revenue Market Share by Manufacturers (2017-2022)
  • 3.2.3 Global Top 10 and Top 5 Companies by Influenza Vaccine Revenue in 2021
• 3.3 Global Influenza Vaccine Sales Price by Manufacturers (2017-2022)
• 3.4 Analysis of Competitive Landscape
  • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.4.3 Global Influenza Vaccine Manufacturers Geographical Distribution
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global Influenza Vaccine Sales by Type
  • 4.1.1 Global Influenza Vaccine Historical Sales by Type (2017-2022)
  • 4.1.2 Global Influenza Vaccine Forecasted Sales by Type (2023-2028)
  • 4.1.3 Global Influenza Vaccine Sales Market Share by Type (2017-2028)
• 4.2 Global Influenza Vaccine Revenue by Type
  • 4.2.1 Global Influenza Vaccine Historical Revenue by Type (2017-2022)
  • 4.2.2 Global Influenza Vaccine Forecasted Revenue by Type (2023-2028)
  • 4.2.3 Global Influenza Vaccine Revenue Market Share by Type (2017-2028)
• 4.3 Global Influenza Vaccine Price by Type
  • 4.3.1 Global Influenza Vaccine Price by Type (2017-2022)
  • 4.3.2 Global Influenza Vaccine Price Forecast by Type (2023-2028)

5 Market Size by Application

• 5.1 Global Influenza Vaccine Sales by Application
  • 5.1.1 Global Influenza Vaccine Historical Sales by Application (2017-2022)
  • 5.1.2 Global Influenza Vaccine Forecasted Sales by Application (2023-2028)
  • 5.1.3 Global Influenza Vaccine Sales Market Share by Application (2017-2028)
• 5.2 Global Influenza Vaccine Revenue by Application
  • 5.2.1 Global Influenza Vaccine Historical Revenue by Application (2017-2022)
  • 5.2.2 Global Influenza Vaccine Forecasted Revenue by Application (2023-2028)
  • 5.2.3 Global Influenza Vaccine Revenue Market Share by Application (2017-2028)
• 5.3 Global Influenza Vaccine Price by Application
  • 5.3.1 Global Influenza Vaccine Price by Application (2017-2022)
  • 5.3.2 Global Influenza Vaccine Price Forecast by Application (2023-2028)

6 North America

• 6.1 North America Influenza Vaccine Market Size by Type
  • 6.1.1 North America Influenza Vaccine Sales by Type (2017-2028)
  • 6.1.2 North America Influenza Vaccine Revenue by Type (2017-2028)
• 6.2 North America Influenza Vaccine Market Size by Application
  • 6.2.1 North America Influenza Vaccine Sales by Application (2017-2028)
  • 6.2.2 North America Influenza Vaccine Revenue by Application (2017-2028)
• 6.3 North America Influenza Vaccine Market Size by Country
  • 6.3.1 North America Influenza Vaccine Sales by Country (2017-2028)
  • 6.3.2 North America Influenza Vaccine Revenue by Country (2017-2028)
  • 6.3.3 U.S.
  • 6.3.4 Canada

7 Europe

• 7.1 Europe Influenza Vaccine Market Size by Type
  • 7.1.1 Europe Influenza Vaccine Sales by Type (2017-2028)
  • 7.1.2 Europe Influenza Vaccine Revenue by Type (2017-2028)
• 7.2 Europe Influenza Vaccine Market Size by Application
  • 7.2.1 Europe Influenza Vaccine Sales by Application (2017-2028)
  • 7.2.2 Europe Influenza Vaccine Revenue by Application (2017-2028)
• 7.3 Europe Influenza Vaccine Market Size by Country
  • 7.3.1 Europe Influenza Vaccine Sales by Country (2017-2028)
  • 7.3.2 Europe Influenza Vaccine Revenue by Country (2017-2028)
  • 7.3.3 Germany
  • 7.3.4 France
  • 7.3.5 U.K.
  • 7.3.6 Italy
  • 7.3.7 Russia

8 Asia Pacific

• 8.1 Asia Pacific Influenza Vaccine Market Size by Type
  • 8.1.1 Asia Pacific Influenza Vaccine Sales by Type (2017-2028)
  • 8.1.2 Asia Pacific Influenza Vaccine Revenue by Type (2017-2028)
• 8.2 Asia Pacific Influenza Vaccine Market Size by Application
  • 8.2.1 Asia Pacific Influenza Vaccine Sales by Application (2017-2028)
  • 8.2.2 Asia Pacific Influenza Vaccine Revenue by Application (2017-2028)
• 8.3 Asia Pacific Influenza Vaccine Market Size by Region
  • 8.3.1 Asia Pacific Influenza Vaccine Sales by Region (2017-2028)
  • 8.3.2 Asia Pacific Influenza Vaccine Revenue by Region (2017-2028)
  • 8.3.3 China
  • 8.3.4 Japan
  • 8.3.5 South Korea
  • 8.3.6 India
  • 8.3.7 Australia
  • 8.3.8 China Taiwan
  • 8.3.9 Indonesia
  • 8.3.10 Thailand
  • 8.3.11 Malaysia

9 Latin America

• 9.1 Latin America Influenza Vaccine Market Size by Type
  • 9.1.1 Latin America Influenza Vaccine Sales by Type (2017-2028)
  • 9.1.2 Latin America Influenza Vaccine Revenue by Type (2017-2028)
• 9.2 Latin America Influenza Vaccine Market Size by Application
  • 9.2.1 Latin America Influenza Vaccine Sales by Application (2017-2028)
  • 9.2.2 Latin America Influenza Vaccine Revenue by Application (2017-2028)
• 9.3 Latin America Influenza Vaccine Market Size by Country
  • 9.3.1 Latin America Influenza Vaccine Sales by Country (2017-2028)
  • 9.3.2 Latin America Influenza Vaccine Revenue by Country (2017-2028)
  • 9.3.3 Mexico
  • 9.3.4 Brazil
  • 9.3.5 Argentina

10 Middle East and Africa

• 10.1 Middle East and Africa Influenza Vaccine Market Size by Type
  • 10.1.1 Middle East and Africa Influenza Vaccine Sales by Type (2017-2028)
  • 10.1.2 Middle East and Africa Influenza Vaccine Revenue by Type (2017-2028)
• 10.2 Middle East and Africa Influenza Vaccine Market Size by Application
  • 10.2.1 Middle East and Africa Influenza Vaccine Sales by Application (2017-2028)
  • 10.2.2 Middle East and Africa Influenza Vaccine Revenue by Application (2017-2028)
• 10.3 Middle East and Africa Influenza Vaccine Market Size by Country
  • 10.3.1 Middle East and Africa Influenza Vaccine Sales by Country (2017-2028)
  • 10.3.2 Middle East and Africa Influenza Vaccine Revenue by Country (2017-2028)
  • 10.3.3 Turkey
  • 10.3.4 Saudi Arabia

11 Company Profiles

• 11.1 CSL
  • 11.1.1 CSL Corporation Information
  • 11.1.2 CSL Overview
  • 11.1.3 CSL Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.1.4 CSL Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 CSL Recent Developments
• 11.2 GSK
  • 11.2.1 GSK Corporation Information
  • 11.2.2 GSK Overview
  • 11.2.3 GSK Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.2.4 GSK Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 GSK Recent Developments
• 11.3 Sanofi Pasteur
  • 11.3.1 Sanofi Pasteur Corporation Information
  • 11.3.2 Sanofi Pasteur Overview
  • 11.3.3 Sanofi Pasteur Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.3.4 Sanofi Pasteur Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 Sanofi Pasteur Recent Developments
• 11.4 Mylan
  • 11.4.1 Mylan Corporation Information
  • 11.4.2 Mylan Overview
  • 11.4.3 Mylan Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.4.4 Mylan Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 Mylan Recent Developments
• 11.5 Hulan Bio
  • 11.5.1 Hulan Bio Corporation Information
  • 11.5.2 Hulan Bio Overview
  • 11.5.3 Hulan Bio Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.5.4 Hulan Bio Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 Hulan Bio Recent Developments
• 11.6 AstraZeneca
  • 11.6.1 AstraZeneca Corporation Information
  • 11.6.2 AstraZeneca Overview
  • 11.6.3 AstraZeneca Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.6.4 AstraZeneca Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.6.5 AstraZeneca Recent Developments
• 11.7 CCBIO
  • 11.7.1 CCBIO Corporation Information
  • 11.7.2 CCBIO Overview
  • 11.7.3 CCBIO Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.7.4 CCBIO Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.7.5 CCBIO Recent Developments

12 Industry Chain and Sales Channels Analysis

• 12.1 Influenza Vaccine Industry Chain Analysis
• 12.2 Influenza Vaccine Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Influenza Vaccine Production Mode & Process
• 12.4 Influenza Vaccine Sales and Marketing
  • 12.4.1 Influenza Vaccine Sales Channels
  • 12.4.2 Influenza Vaccine Distributors
• 12.5 Influenza Vaccine Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

• 13.1 Influenza Vaccine Industry Trends
• 13.2 Influenza Vaccine Market Drivers
• 13.3 Influenza Vaccine Market Challenges
• 13.4 Influenza Vaccine Market Restraints

14 Key Findings in The Global Influenza Vaccine Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details
• 15.3 Disclaimer

• Table 1. Global Influenza Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
• Table 2. Major Manufacturers of Trivalent Influenza Vaccine
• Table 3. Major Manufacturers of Quadrivalent Influenza Vaccine
• Table 4. Global Influenza Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
• Table 5. Global Influenza Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
• Table 6. Global Influenza Vaccine Sales by Region (2017-2022) & (M Doses)
• Table 7. Global Influenza Vaccine Sales Market Share by Region (2017-2022)
• Table 8. Global Influenza Vaccine Sales by Region (2023-2028) & (M Doses)
• Table 9. Global Influenza Vaccine Sales Market Share by Region (2023-2028)
• Table 10. Global Influenza Vaccine Revenue by Region (2017-2022) & (US$ Million)
• Table 11. Global Influenza Vaccine Revenue Market Share by Region (2017-2022)
• Table 12. Global Influenza Vaccine Revenue by Region (2023-2028) & (US$ Million)
• Table 13. Global Influenza Vaccine Revenue Market Share by Region (2023-2028)
• Table 14. Global Influenza Vaccine Sales by Manufacturers (2017-2022) & (M Doses)
• Table 15. Global Influenza Vaccine Sales Share by Manufacturers (2017-2022)
• Table 16. Global Influenza Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
• Table 17. Global Influenza Vaccine Revenue Share by Manufacturers (2017-2022)
• Table 18. Influenza Vaccine Price by Manufacturers (2017-2022) &(USD/Doses)
• Table 19. Global Influenza Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
• Table 20. Global Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Vaccine as of 2021)
• Table 21. Influenza Vaccine Manufacturing Base Distribution and Headquarters
• Table 22. Manufacturers Influenza Vaccine Product Offered
• Table 23. Date of Manufacturers Enter into Influenza Vaccine Market
• Table 24. Mergers & Acquisitions, Expansion Plans
• Table 25. Global Influenza Vaccine Sales by Type (2017-2022) & (M Doses)
• Table 26. Global Influenza Vaccine Sales by Type (2023-2028) & (M Doses)
• Table 27. Global Influenza Vaccine Sales Share by Type (2017-2022)
• Table 28. Global Influenza Vaccine Sales Share by Type (2023-2028)
• Table 29. Global Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
• Table 30. Global Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
• Table 31. Global Influenza Vaccine Revenue Share by Type (2017-2022)
• Table 32. Global Influenza Vaccine Revenue Share by Type (2023-2028)
• Table 33. Influenza Vaccine Price by Type (2017-2022) & (USD/Doses)
• Table 34. Global Influenza Vaccine Price Forecast by Type (2023-2028) & (USD/Doses)
• Table 35. Global Influenza Vaccine Sales by Application (2017-2022) & (M Doses)
• Table 36. Global Influenza Vaccine Sales by Application (2023-2028) & (M Doses)
• Table 37. Global Influenza Vaccine Sales Share by Application (2017-2022)
• Table 38. Global Influenza Vaccine Sales Share by Application (2023-2028)
• Table 39. Global Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
• Table 40. Global Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
• Table 41. Global Influenza Vaccine Revenue Share by Application (2017-2022)
• Table 42. Global Influenza Vaccine Revenue Share by Application (2023-2028)
• Table 43. Influenza Vaccine Price by Application (2017-2022) & (USD/Doses)
• Table 44. Global Influenza Vaccine Price Forecast by Application (2023-2028) & (USD/Doses)
• Table 45. North America Influenza Vaccine Sales by Type (2017-2022) & (M Doses)
• Table 46. North America Influenza Vaccine Sales by Type (2023-2028) & (M Doses)
• Table 47. North America Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
• Table 48. North America Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
• Table 49. North America Influenza Vaccine Sales by Application (2017-2022) & (M Doses)
• Table 50. North America Influenza Vaccine Sales by Application (2023-2028) & (M Doses)
• Table 51. North America Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
• Table 52. North America Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
• Table 53. North America Influenza Vaccine Sales by Country (2017-2022) & (M Doses)
• Table 54. North America Influenza Vaccine Sales by Country (2023-2028) & (M Doses)
• Table 55. North America Influenza Vaccine Revenue by Country (2017-2022) & (US$ Million)
• Table 56. North America Influenza Vaccine Revenue by Country (2023-2028) & (US$ Million)
• Table 57. Europe Influenza Vaccine Sales by Type (2017-2022) & (M Doses)
• Table 58. Europe Influenza Vaccine Sales by Type (2023-2028) & (M Doses)
• Table 59. Europe Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
• Table 60. Europe Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
• Table 61. Europe Influenza Vaccine Sales by Application (2017-2022) & (M Doses)
• Table 62. Europe Influenza Vaccine Sales by Application (2023-2028) & (M Doses)
• Table 63. Europe Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
• Table 64. Europe Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
• Table 65. Europe Influenza Vaccine Sales by Country (2017-2022) & (M Doses)
• Table 66. Europe Influenza Vaccine Sales by Country (2023-2028) & (M Doses)
• Table 67. Europe Influenza Vaccine Revenue by Country (2017-2022) & (US$ Million)
• Table 68. Europe Influenza Vaccine Revenue by Country (2023-2028) & (US$ Million)
• Table 69. Asia Pacific Influenza Vaccine Sales by Type (2017-2022) & (M Doses)
• Table 70. Asia Pacific Influenza Vaccine Sales by Type (2023-2028) & (M Doses)
• Table 71. Asia Pacific Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
• Table 72. Asia Pacific Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
• Table 73. Asia Pacific Influenza Vaccine Sales by Application (2017-2022) & (M Doses)
• Table 74. Asia Pacific Influenza Vaccine Sales by Application (2023-2028) & (M Doses)
• Table 75. Asia Pacific Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
• Table 76. Asia Pacific Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
• Table 77. Asia Pacific Influenza Vaccine Sales by Region (2017-2022) & (M Doses)
• Table 78. Asia Pacific Influenza Vaccine Sales by Region (2023-2028) & (M Doses)
• Table 79. Asia Pacific Influenza Vaccine Revenue by Region (2017-2022) & (US$ Million)
• Table 80. Asia Pacific Influenza Vaccine Revenue by Region (2023-2028) & (US$ Million)
• Table 81. Latin America Influenza Vaccine Sales by Type (2017-2022) & (M Doses)
• Table 82. Latin America Influenza Vaccine Sales by Type (2023-2028) & (M Doses)
• Table 83. Latin America Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
• Table 84. Latin America Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
• Table 85. Latin America Influenza Vaccine Sales by Application (2017-2022) & (M Doses)
• Table 86. Latin America Influenza Vaccine Sales by Application (2023-2028) & (M Doses)
• Table 87. Latin America Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
• Table 88. Latin America Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
• Table 89. Latin America Influenza Vaccine Sales by Country (2017-2022) & (M Doses)
• Table 90. Latin America Influenza Vaccine Sales by Country (2023-2028) & (M Doses)
• Table 91. Latin America Influenza Vaccine Revenue by Country (2017-2022) & (US$ Million)
• Table 92. Latin America Influenza Vaccine Revenue by Country (2023-2028) & (US$ Million)
• Table 93. Middle East and Africa Influenza Vaccine Sales by Type (2017-2022) & (M Doses)
• Table 94. Middle East and Africa Influenza Vaccine Sales by Type (2023-2028) & (M Doses)
• Table 95. Middle East and Africa Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
• Table 96. Middle East and Africa Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
• Table 97. Middle East and Africa Influenza Vaccine Sales by Application (2017-2022) & (M Doses)
• Table 98. Middle East and Africa Influenza Vaccine Sales by Application (2023-2028) & (M Doses)
• Table 99. Middle East and Africa Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
• Table 100. Middle East and Africa Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
• Table 101. Middle East and Africa Influenza Vaccine Sales by Country (2017-2022) & (M Doses)
• Table 102. Middle East and Africa Influenza Vaccine Sales by Country (2023-2028) & (M Doses)
• Table 103. Middle East and Africa Influenza Vaccine Revenue by Country (2017-2022) & (US$ Million)
• Table 104. Middle East and Africa Influenza Vaccine Revenue by Country (2023-2028) & (US$ Million)
• Table 105. CSL Corporation Information
• Table 106. CSL Description and Major Businesses
• Table 107. CSL Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
• Table 108. CSL Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
• Table 109. CSL Recent Developments
• Table 110. GSK Corporation Information
• Table 111. GSK Description and Major Businesses
• Table 112. GSK Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
• Table 113. GSK Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
• Table 114. GSK Recent Developments
• Table 115. Sanofi Pasteur Corporation Information
• Table 116. Sanofi Pasteur Description and Major Businesses
• Table 117. Sanofi Pasteur Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
• Table 118. Sanofi Pasteur Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
• Table 119. Sanofi Pasteur Recent Developments
• Table 120. Mylan Corporation Information
• Table 121. Mylan Description and Major Businesses
• Table 122. Mylan Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
• Table 123. Mylan Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
• Table 124. Mylan Recent Developments
• Table 125. Hulan Bio Corporation Information
• Table 126. Hulan Bio Description and Major Businesses
• Table 127. Hulan Bio Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
• Table 128. Hulan Bio Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
• Table 129. Hulan Bio Recent Developments
• Table 130. AstraZeneca Corporation Information
• Table 131. AstraZeneca Description and Major Businesses
• Table 132. AstraZeneca Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
• Table 133. AstraZeneca Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
• Table 134. AstraZeneca Recent Developments
• Table 135. CCBIO Corporation Information
• Table 136. CCBIO Description and Major Businesses
• Table 137. CCBIO Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2017-2022)
• Table 138. CCBIO Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
• Table 139. CCBIO Recent Developments
• Table 140. Key Raw Materials Lists
• Table 141. Raw Materials Key Suppliers Lists
• Table 142. Influenza Vaccine Distributors List
• Table 143. Influenza Vaccine Customers List
• Table 144. Influenza Vaccine Market Trends
• Table 145. Influenza Vaccine Market Drivers
• Table 146. Influenza Vaccine Market Challenges
• Table 147. Influenza Vaccine Market Restraints
• Table 148. Research Programs/Design for This Report
• Table 149. Key Data Information from Secondary Sources
• Table 150. Key Data Information from Primary Sources

List of Figures

• Figure 1. Influenza Vaccine Product Picture
• Figure 3. Global Influenza Vaccine Market Share by Type in 2021 & 2028
• Figure 3. Trivalent Influenza Vaccine Product Picture
• Figure 4. Quadrivalent Influenza Vaccine Product Picture
• Figure 5. Global Influenza Vaccine Market Share by Application in 2021 & 2028
• Figure 6. For Children (6 months to 3 years)
• Figure 7. For Adults and Children over 3 years
• Figure 8. Influenza Vaccine Report Years Considered
• Figure 9. Global Influenza Vaccine Sales 2017-2028 (M Doses)
• Figure 10. Global Influenza Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
• Figure 11. Global Influenza Vaccine Revenue 2017-2028 (US$ Million)
• Figure 12. Global Influenza Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
• Figure 13. Global Influenza Vaccine Sales Market Share by Region (2017-2022)
• Figure 14. Global Influenza Vaccine Sales Market Share by Region (2023-2028)
• Figure 15. North America Influenza Vaccine Sales YoY (2017-2028) & (M Doses)
• Figure 16. North America Influenza Vaccine Revenue YoY (2017-2028) & (US$ Million)
• Figure 17. Europe Influenza Vaccine Sales YoY (2017-2028) & (M Doses)
• Figure 18. Europe Influenza Vaccine Revenue YoY (2017-2028) & (US$ Million)
• Figure 19. Asia-Pacific Influenza Vaccine Sales YoY (2017-2028) & (M Doses)
• Figure 20. Asia-Pacific Influenza Vaccine Revenue YoY (2017-2028) & (US$ Million)
• Figure 21. Latin America Influenza Vaccine Sales YoY (2017-2028) & (M Doses)
• Figure 22. Latin America Influenza Vaccine Revenue YoY (2017-2028) & (US$ Million)
• Figure 23. Middle East & Africa Influenza Vaccine Sales YoY (2017-2028) & (M Doses)
• Figure 24. Middle East & Africa Influenza Vaccine Revenue YoY (2017-2028) & (US$ Million)
• Figure 25. The Influenza Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
• Figure 26. The Top 5 and 10 Largest Manufacturers of Influenza Vaccine in the World: Market Share by Influenza Vaccine Revenue in 2021
• Figure 27. Global Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
• Figure 28. Global Influenza Vaccine Sales Market Share by Type (2017-2028)
• Figure 29. Global Influenza Vaccine Revenue Market Share by Type (2017-2028)
• Figure 30. Global Influenza Vaccine Sales Market Share by Application (2017-2028)
• Figure 31. Global Influenza Vaccine Revenue Market Share by Application (2017-2028)
• Figure 32. North America Influenza Vaccine Sales Market Share by Type (2017-2028)
• Figure 33. North America Influenza Vaccine Revenue Market Share by Type (2017-2028)
• Figure 34. North America Influenza Vaccine Sales Market Share by Application (2017-2028)
• Figure 35. North America Influenza Vaccine Revenue Market Share by Application (2017-2028)
• Figure 36. North America Influenza Vaccine Sales Share by Country (2017-2028)
• Figure 37. North America Influenza Vaccine Revenue Share by Country (2017-2028)
• Figure 38. U.S. Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 39. Canada Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 40. Europe Influenza Vaccine Sales Market Share by Type (2017-2028)
• Figure 41. Europe Influenza Vaccine Revenue Market Share by Type (2017-2028)
• Figure 42. Europe Influenza Vaccine Sales Market Share by Application (2017-2028)
• Figure 43. Europe Influenza Vaccine Revenue Market Share by Application (2017-2028)
• Figure 44. Europe Influenza Vaccine Sales Share by Country (2017-2028)
• Figure 45. Europe Influenza Vaccine Revenue Share by Country (2017-2028)
• Figure 46. Germany Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 47. France Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 48. U.K. Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 49. Italy Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 50. Russia Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 51. Asia Pacific Influenza Vaccine Sales Market Share by Type (2017-2028)
• Figure 52. Asia Pacific Influenza Vaccine Revenue Market Share by Type (2017-2028)
• Figure 53. Asia Pacific Influenza Vaccine Sales Market Share by Application (2017-2028)
• Figure 54. Asia Pacific Influenza Vaccine Revenue Market Share by Application (2017-2028)
• Figure 55. Asia Pacific Influenza Vaccine Sales Share by Region (2017-2028)
• Figure 56. Asia Pacific Influenza Vaccine Revenue Share by Region (2017-2028)
• Figure 57. China Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 58. Japan Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 59. South Korea Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 60. India Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 61. Australia Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 62. China Taiwan Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 63. Indonesia Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 64. Thailand Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 65. Malaysia Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 66. Latin America Influenza Vaccine Sales Market Share by Type (2017-2028)
• Figure 67. Latin America Influenza Vaccine Revenue Market Share by Type (2017-2028)
• Figure 68. Latin America Influenza Vaccine Sales Market Share by Application (2017-2028)
• Figure 69. Latin America Influenza Vaccine Revenue Market Share by Application (2017-2028)
• Figure 70. Latin America Influenza Vaccine Sales Share by Country (2017-2028)
• Figure 71. Latin America Influenza Vaccine Revenue Share by Country (2017-2028)
• Figure 72. Mexico Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 73. Brazil Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 74. Argentina Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 75. Middle East and Africa Influenza Vaccine Sales Market Share by Type (2017-2028)
• Figure 76. Middle East and Africa Influenza Vaccine Revenue Market Share by Type (2017-2028)
• Figure 77. Middle East and Africa Influenza Vaccine Sales Market Share by Application (2017-2028)
• Figure 78. Middle East and Africa Influenza Vaccine Revenue Market Share by Application (2017-2028)
• Figure 79. Middle East and Africa Influenza Vaccine Sales Share by Country (2017-2028)
• Figure 80. Middle East and Africa Influenza Vaccine Revenue Share by Country (2017-2028)
• Figure 81. Turkey Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 82. Saudi Arabia Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 83. UAE Influenza Vaccine Revenue (2017-2028) & (US$ Million)
• Figure 84. Influenza Vaccine Value Chain
• Figure 85. Influenza Vaccine Production Process
• Figure 86. Channels of Distribution
• Figure 87. Distributors Profiles
• Figure 88. Bottom-up and Top-down Approaches for This Report
• Figure 89. Data Triangulation
• Figure 90. Key Executives Interviewed